European Journal of Cancer
Volume 39, Issue 9 , Pages 1228-1233, June 2003

Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

  • L. Mauriac

      Affiliations

    • Institut Bergonié, Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, 229, cours de l'Argonne, 33076 Bordeaux, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-5-5633-3333; fax: +33-5-5633-3385
    • ,
  • J.E. Pippen

      Affiliations

    • Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA
    • ,
  • J. Quaresma Albano

      Affiliations

    • Instituto Portugues De Oncologia De Coimbra, Coimbra, Portugal
    • ,
  • S.Z. Gertler

      Affiliations

    • Ottawa Regional Cancer Center, Ottawa, ON, Canada
    • ,
  • C.K. Osborne

      Affiliations

    • Breast Center at Baylor College of Medicine and Methodist Hospital, Houston, TX, USA

Received 6 September 2002; received in revised form 2 January 2003; accepted 26 February 2003.

Full Text Available

  • Purchase this article for  31.50 USD

    Access is available for 24 hours.

    (Login or Register to purchase)

  • Subscribe to this title
  • Claim access now

    Current subscribers


    • PII: S0959-8049(03)00199-0

    doi:10.1016/S0959-8049(03)00199-0

    European Journal of Cancer
    Volume 39, Issue 9 , Pages 1228-1233, June 2003